William Janssen, PhD

William E. Janssen, PhD

Member, St. Jude Faculty

Departments

Bone Marrow Transplantation & Cellular Therapy

Contact Information

William Janssen, PhD
Bone Marrow Transplantation & Cellular Therapy
MS 310, Room I-4103
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: william.janssen@stjude.org
Phone: (901) 595-5646
FAX: (901) 595-3966

Education

BA - University of California, Berkeley, California
MS - University of Colorado, Denver Health Sciences Center, Denver, Colorado
PhD - State University of New York at Buffalo, Buffalo, New York


Research Interests


Selected Publications

Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu X-Z, Janssen W, Anasetti C. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood 122(13):2251-2261, 2013.

Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mule JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35(8):615-620, 2012.

Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 97(12):1882-1889, 2012.

Perkins JB, Shapiro JF, Bookout RN, Yee GC, Anasetti C, Janssen WE, Fernandez HF. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes. Am J Hematol 87(7):673-677, 2012.

Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy 4(4):373-382, 2012.

Janssen WE,Ayala E, Field T, Ochoa L, Rahn D, Hackett M, Coyle D, Tomblyn M, Smilee RC, Anasetti C, Fernandez HF. Apheresis and Transplant of Hematopoietic Progenitor Cells from Donors Aged Sixty and Above. Bone Marrow Transplantation 47(12):1520-1525, 2012.

Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys 82(2):924-32, 2012.

Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biology of Blood and Marrow Transplantation 17(3): 384-93, 2011.

Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 16:937-47, 2010. (note shared senior authorship)

Janssen WE,Ribickas A, Meyer LV, Smilee RC. Large-scale Ficoll gradient separations using a commercially available, effectively closed, system. Cytotherapy 12:418-24, 2010.

Gunter KC, Caplan AL, Mason C, Salzman R, Janssen WE, Nichols K, Bouzas LF, Lanza F, Levine BL, Rasko JE, Shimosaka A, Horwitz E. Cell therapy medical tourism: time for action. Cytotherapy 12(8):965-968, 2010.

Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 45:255-60, 2010.

Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opinion on Biological Therapy 10:983-91, 2010.

Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol 14:869-84, 2007.

Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 31:72-80, 2008. (note shared senior authorship)

Janssen W. Data management in the cell therapy production facility: the batch process record (BPR). Cytotherapy 10:227-37, 2008.

Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12:878-87, 2006.

Fallon P, Gentry T, Balber AE, Boulware D, Janssen WE, Smilee R, Storms RW, Smith C. Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. British Journal of Haematology 122:99-108, 2003.

Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urology 167:1995, 2002.

Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, Freeman TB, Saporta S, Janssen W, Patel N, Cooper DR, Sanberg PR. Adult bone marrow stromal cells differentiate into neural cells in vitro. Experimental Neurology 164:247-56, 2000.

Bashey A, Corringham S, Gilpin E, Fields KK, Smilee RC, DeFrancisco C, Santos-Ada O, Holman P, Carrier E, Ho AD, Lane TA, Ball ED, Janssen WE, Law P. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. Cytotherapy 2:195-200, 2000. (note shared senior authorship)

Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 20:653-6, 1997.

Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 14:1868-76, 1996.

Ballester OF, Agaliotis DP, Hiemenz JW, Janssen WE, Fields KK, Zorksy PE, Goldstein SC, Perkins JB, Elfenbein GJ. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Bone Marrow Transplant 18:9-14, 1996.

Janssen WE, Smilee RC, Elfenbein GJ. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. J Hematother 4:139-40, 1995.

Janssen WE. Mobilization of peripheral blood stem cells for autologous transplantation. Methods, mechanisms, and role in accelerating hematopoietic recovery. Annals of the New York Academy of Sciences 770:116-29, 1995.

Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 13:323-32, 1995.

Elfenbein GJ, Janssen WE, Perkins JB. Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. Annals of the New York Academy of Sciences 770:315-38, 1995.

Last update: July 2014